WallStreetZenWallStreetZen

NASDAQ: ZYME
Zymeworks Inc Stock

$11.74-0.30 (-2.49%)
Updated Feb 21, 2024
ZYME Price
$11.74
Fair Value Price
N/A
Market Cap
$821.82M
52 Week Low
$6.02
52 Week High
$12.53
P/E
3.62x
P/B
1.94x
P/S
0.97x
PEG
0.04x
Dividend Yield
N/A
Revenue
$461.58M
Earnings
$205.24M
Gross Margin
100%
Operating Margin
47.75%
Profit Margin
44.5%
Debt to Equity
0.31
Operating Cash Flow
$195M
Beta
0.92
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ZYME Overview

Zymeworks Incorporated is a clinical-stage biopharmaceutical company that develops and commercializes cancer-treating biotherapeutics. The company's lead candidates include zanidatamab, a bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has partnerships with Merck, Eli Lilly, Bristol-Myers, and GlaxoSmithKline, among others. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ZYME scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ZYME ($11.74) is trading below its intrinsic value of $125.52, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ZYME is good value based on its earnings relative to its share price (3.62x), compared to the US market average (28.8x)
P/E vs Market Valuation
ZYME is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more ZYME due diligence checks available for Premium users.

Be the first to know about important ZYME news, forecast changes, insider trades & much more!

Valuation

ZYME price to earnings (PE)

For valuing profitable companies with steady earnings
Company
3.62x
Industry
16.04x
Market
28.8x
ZYME is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ZYME is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

ZYME price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.94x
Industry
5.97x
ZYME is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ZYME price to earnings growth (PEG)

For valuing profitable companies with growth potential
ZYME is good value based... subscribe to Premium to read more.
PEG Value Valuation

ZYME's financial health

Profit margin

Revenue
$16.5M
Net Income
-$28.7M
Profit Margin
-173.8%
ZYME's Earnings (EBIT) of $220.40M... subscribe to Premium to read more.
Interest Coverage Financials
ZYME's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$556.4M
Liabilities
$132.0M
Debt to equity
0.31
ZYME's short-term assets ($374.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZYME's short-term assets ($374.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZYME's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ZYME's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$42.7M
Investing
-$7.0M
Financing
$1.9M
ZYME's operating cash flow ($195.10M)... subscribe to Premium to read more.
Debt Coverage Financials

ZYME vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ZYME$821.82M-2.49%3.62x1.94x
PRME$826.28M+5.73%-11.47x4.26x
TYRA$828.02M+2.12%-13.93x3.73x
AUPH$830.11M+2.68%-10.63x2.20x
RGNX$809.45M-0.76%-3.07x2.23x

Zymeworks Stock FAQ

What is Zymeworks's quote symbol?

(NASDAQ: ZYME) Zymeworks trades on the NASDAQ under the ticker symbol ZYME. Zymeworks stock quotes can also be displayed as NASDAQ: ZYME.

If you're new to stock investing, here's how to buy Zymeworks stock.

What is the 52 week high and low for Zymeworks (NASDAQ: ZYME)?

(NASDAQ: ZYME) Zymeworks's 52-week high was $12.53, and its 52-week low was $6.02. It is currently -6.3% from its 52-week high and 95.18% from its 52-week low.

How much is Zymeworks stock worth today?

(NASDAQ: ZYME) Zymeworks currently has 70,001,987 outstanding shares. With Zymeworks stock trading at $11.74 per share, the total value of Zymeworks stock (market capitalization) is $821.82M.

Zymeworks stock was originally listed at a price of $13.00 in Apr 28, 2017. If you had invested in Zymeworks stock at $13.00, your return over the last 6 years would have been -9.69%, for an annualized return of -1.68% (not including any dividends or dividend reinvestments).

How much is Zymeworks's stock price per share?

(NASDAQ: ZYME) Zymeworks stock price per share is $11.74 today (as of Feb 21, 2024).

What is Zymeworks's Market Cap?

(NASDAQ: ZYME) Zymeworks's market cap is $821.82M, as of Feb 22, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Zymeworks's market cap is calculated by multiplying ZYME's current stock price of $11.74 by ZYME's total outstanding shares of 70,001,987.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.